Igenomix portfolio includes pioneering genetic tests to help reproductive-health professionals to analyse and treat their patients before, during and after their reproductive journey.
Vitrolife delivers innovative, high-quality products to ensure optimal care at every stage of the IVF journey, from error prevention and gamete handling to embryo evaluation and cryopreservation.
Annual Report
Vitrolife Group Annual and Sustainability Report for 2025
We are pleased to announce the release of Vitrolife Group’s Annual Report for 2025.
Despite a volatile market, we delivered a resilient performance, continued to gain market share in key regions, and maintained our strategic focus on growth, innovation, and operational excellence.
Latest financial report
Interim report Q1, 2026: Strong growth in Consumables and Technologies
A good start to the year with 5% organic growth in local currencies, building on solid momentum and proactively navigating dynamic market conditions, while maintaining a clear focus on executing our long-term strategy.
Press Releases
Financial Calendar
-
05 May 2026
Annual General Meeting 2026
-
16 Jul 2026
Interim report Q2, 2026
-
22 Oct 2026
Interim report Q3, 2026
Careers
The Vitrolife Group offers an attractive workplace with an opportunity to work for a higher purpose, a purpose that makes a difference in people’s lives worldwide.
Investor relations
Our aim is to have a strong capital base to enable continued high growth, both organically and through acquisitions. We strive to achieve growth through profitability.
Sustainability
Ensuring sustainability in everything we do is one of our key strategic priorities. Learn more on our approach and sustainability themes.